Please use this identifier to cite or link to this item:
Title: Design and application of a medication assessment tool for secondary prevention of stroke
Authors: Gauci, Marise
Wirth, Francesca
Camilleri, Liberato
Azzopardi, Lilian M.
Serracino-Inglott, Anthony
Keywords: Older people -- Case studies
Older people -- Care
Drugs -- Dosage -- Reduction
Issue Date: 2017
Publisher: Springer Netherlands
Citation: Gauci, M., Wirth, F., Camilleri, L., Azzopardi, L. M., & Serracino-Inglott, A. (2017). Design and application of a medication assessment tool for secondary prevention of stroke. International Journal of Clinical Pharmacy, 39(5), 1008-1012.
Abstract: Background Optimisation of drug therapy is essential in the care of older persons and may be facilitated by application of medication assessment tools (MATs). Objective To design, psychometrically evaluate and apply an innovative MAT for secondary prevention of ischaemic stroke with particular relevance to older persons. Method Review criteria were selected from clinical practice guidelines and MAT-CVA was developed, validated and tested for reliability and feasibility. MAT-CVA was applied to 150 patients with a diagnosis of ischaemic stroke or transient ischaemic attack admitted to a rehabilitation hospital. Results MAT-CVA consists of 17 criteria sectioned into antithrombotic, lipid lowering, antihypertensive and glycaemic therapy. Content validity was demonstrated for all criteria. Reliability was confirmed with kappa values of 0.80 for both inter- and intraobserver agreements. Mean application time for the two observers was 5.55 and 6.56 min. Adherence to applicable criteria was 55% and justified non-adherence was 22.3%. Non-adherence was predominantly evident for prescription of anticoagulation in concurrent atrial fibrillation (36.4%), thiazide diuretics ± angiotensin converting enzyme inhibitors for hypertension (26.8%) and dipyridamole at the recommended dose (24.0%). Conclusion Application of MATCVA indicated good overall adherence and identified gaps in clinical performance which may be targeted to enhance drug therapy optimisation.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
  Restricted Access
238.59 kBAdobe PDFView/Open Request a copy

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.